| 翻訳と辞書 |
| Paul Billings ： ウィキペディア英語版 |
Paul Billings
Paul Billings is an American doctor, lecturer, researcher, professor, and consultant on genetic information. His major research interests include the impact of genomic information and biotechnology on society, the integration of genomics and diagnostics in to health and medical care and individualized genomic medicine. Dr. Paul Billings is the author of nearly 200 publications and books on genomic medicine, has spoken at numerous medical conferences, and appeared on talk shows such as The Oprah Show and 60 Minutes.He is currently an Executive in Residence at the California Innovation Center of Johnson & Johnson and the Medical Director of the IMPACT Cancer Care Program Thermo Fisher Scientific (TFS).
==Biography ==
Board certified internist and clinical geneticist, Dr. Paul R. Billings is an Executive-in-Residence at the California Innovation Center of Johnson & Johnson and the Medical Director of the IMPACT Cancer Care Program Thermo Fisher Scientific (TFS). Recently, Dr. Billings was the Chief Medical Officer of Life Technologies Inc. (LIFE) and then the CMO (consulting) of the Genetic Sciences Division of TFS both unique positions aimed at improving patient care through expanding the use of medically relevant genomic technologies in clinical settings. Dr. Billings has extensive expertise and health care experience in the areas of genomics and molecular medicine. He has served on the Scientific Advisory Board of the Food and Drug Administration and the Genomic Medicine Advisory Committee at the Department of Veterans Affairs. He currently is a Director of the Personalized Medicine Coalition and a member of the IOM Genomics Roundtable. Prior to the appointments at Lifetech and TFS, Dr. Billings was the Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital, the largest community hospital in the Silicon Valley. He was also a member of the United States Department of Health and Human Services Secretary's Advisory Committee on Genetics, Health and Society before it was disbanded. Dr. Billings has had a distinguished career as a physician and researcher. He has been a founder or chief executive officer of companies involved in genetic and diagnostic medicine including GeneSage Inc., Omicia Inc., CELLective Dx Corporation and was senior vice president for corporate development at Laboratory Corporation of America Holdings (NYSE; LH). He has held academic appointments at some of the most prestigious universities in the United States including Harvard University, U.C. San Francisco, Stanford University and U.C. Berkeley, and has served as a physician at a number of leading medical centers. He is the author of nearly 200 publications and books on experimental and clinical medicine. His work on genetic discrimination was instrumental in the creation and passage of the federal Genetic Information Non-Discrimination Act of 2008. Dr. Billings holds an M.D. from Harvard Medical School and a Ph.D. in immunology from Harvard University. Prior to their recent transactions, Dr. Billings was a Director of Ancestry.com (NASDAQ: ACOM), the Executive Chairman of Signature Genomics Inc., and a Founder of the Cordblood Registry, Inc. He is currently a Board Director of Trovagene Inc. and CollabRX Inc., both publicly traded personalized medicine companies in the United States. He also acts as the Chief Medical Officer of Omicia, Inc. He serves on many other for profit and not for profit Boards including the Council for Responsible Genetics, the country’s oldest independent biotechnology “watchdog” organization.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Paul Billings」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|